Please assess the completion status of the following clinical trial:

Trial Title: Comparison of Rituximab Induction Therapy Followed by Glatiramer Acetate

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* 18 through 55 years of age~* Patients with CIS demonstrating one unifocal neurological event AND at least 2 T2-weighted brain lesions measuring a minimum of 6mm in diameter by MRI analysis; or a definite diagnosis of RMS, as defined by the 2005 revised McDonald criteria(1, 2), and have had at least one clinically defined relapse within the past year OR one GEL on an MRI within the past year~* Women of child-bearing potential must agree to practice an acceptable method of birth control~* No evidence of progressive multifocal leukoencephalopathy (PML) or primary central nervous system (PCNS) lymphoma~* Neurologically stable with no evidence of relapse or corticosteroid treatment within 30 days prior to randomization~* Subject must be able and willing to give meaningful, written informed consent prior to participation in the trial, in accordance with local regulatory requirements.~Exclusion Criteria:~* ≥ 15 GELs on baseline MRI~* Treatment with interferon β, natalizumab, or fingolimod within three months of randomization~* Treatment with mitoxantrone, cyclophosphamide, or any other chemotherapeutic agent for MS or malignancy within 12 months of randomization~* Attenuated live virus vaccination within 4 weeks of randomization~* Positive urine and serum pregnancy test at screening or baseline visit~* Any prior treatment with alemtuzumab or cladribine~* Unable to tolerate GA~* History of cardiac arrhythmias, angina or any other significant cardiac abnormalities~* History of clinically significant chronic disease of the immune system or a known immunodeficiency syndrome (HIV) other than MS~* White Blood Cell count of less than 2.5\*10\^9/L or lymphocyte count below 0.4\*10\^9/L~* Positive for any evidence of past, or current, hepatitis B and/or C infection~* History or presence of malignancy (except basal cell carcinoma)~* Clinically significant alcohol or drug abuse within past two years~* Any medical, psychiatric or other condition that could result in a subject not being able to give fully informed consent, or to comply with the protocol requirements~* Inability to undergo MRI scans or history of hypersensitivity to gadolinium- diethylenetriamine penta-acetic acid (DTPA)~* Participation in any clinical study evaluating another investigational drug or therapy within three months prior to randomization~* Any other condition that, in the Investigator's opinion, makes the subject unsuitable for participation in the study

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 55 Years
- Healthy Volunteers: f

Study Arms:
- (Placebo and) Glatiramer Acetate (Type: ACTIVE_COMPARATOR): Subjects will receive an intravenous (IV) infusion of placebo (normal saline) on study days 1 (baseline visit) and 15 according to the infusion protocol. On study day 28, all subjects will initiate standard Glatiramer Acetate therapy, 20 mg injected subcutaneously daily.
- Rituximab and Glatiramer Acetate (R-GA) (Type: EXPERIMENTAL): Subjects will receive an intravenous (IV) infusion of 1000 mg of rituximab on study days 1 (baseline visit) and 15 according to the rituximab infusion protocol. On study day 28, subjects will initiate standard Glatiramer Acetate therapy, 20 mg injected subcutaneously daily. There is no placebo arm.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete